

Product datasheet

Anti-p53 (phospho S20) antibody [EPR2156(2)] ab157454

Recombinant RabMAb

★★★★★ [2 Abreviews](#) [3 References](#) [5 Images](#)

Overview

Product name	Anti-p53 (phospho S20) antibody [EPR2156(2)]
Description	Rabbit monoclonal [EPR2156(2)] to p53 (phospho S20)
Host species	Rabbit
Tested applications	Suitable for: WB, IP, Dot blot Unsuitable for: Flow Cyt, ICC/IF or IHC-P
Species reactivity	Reacts with: Human
Immunogen	Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
Positive control	T47D cell lysates, treated with etoposide.
General notes	<p>This product is a recombinant monoclonal antibody, which offers several advantages including:</p> <ul style="list-style-type: none"> - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free production <p>For more information see here.</p> <p>Our RabMAb[®] technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb[®] patents.</p> <p>Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.</p>

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Store at -20°C.
Storage buffer	<p>pH: 7.2</p> <p>Preservative: 0.01% Sodium azide</p> <p>Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant</p>
Purity	Tissue culture supernatant
Clonality	Monoclonal

Clone number EPR2156(2)

Isotype IgG

Applications

The Abpromise guarantee Our **Abpromise guarantee** covers the use of ab157454 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
WB	★★★★★ (1)	1/1000 - 1/5000. Predicted molecular weight: 44 kDa.
IP		1/10 - 1/100.
Dot blot		Use at an assay dependent concentration.

Application notes Is unsuitable for Flow Cyt, ICC/IF or IHC-P.

Target

Function Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.

Tissue specificity Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.

Involvement in disease Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma. Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239]. Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514)

and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck. Defects in TP53 are a cause of lung cancer (LNCr) [MIM:211980]. Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood. Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome.

Sequence similarities

Belongs to the p53 family.

Domain

The nuclear export signal acts as a transcriptional repression domain. The TAD1 and TAD2 motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.

Post-translational modifications

Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.

Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP.

Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.

May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.

Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.


Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.

Sumoylated by SUMO1.

Cellular localization

Cytoplasm; Cytoplasm. Nucleus. Nucleus > PML body. Endoplasmic reticulum. Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2; Nucleus. Cytoplasm. Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli; Nucleus. Cytoplasm. Localized in the nucleus in most cells but found in the cytoplasm in some cells; Nucleus. Cytoplasm. Localized mainly in the nucleus with minor staining in the cytoplasm; Nucleus. Cytoplasm. Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4 and Nucleus. Cytoplasm. Predominantly nuclear but translocates to the cytoplasm following cell stress.

Images



All lanes : Anti-p53 (phospho S20) antibody [EPR2156(2)] (ab157454) at 1/1000 dilution

Lane 1 : T-47D (human mammary gland ductal carcinoma) treated with Etoposide whole cell lysate

Lane 2 : Untreated T47D (human mammary gland ductal carcinoma) whole cell lysate

Lysates/proteins at 10 µg per lane.

Secondary


All lanes : Goat anti-rabbit IgG, (H+L), peroxidase conjugated at 1/1000 dilution

Predicted band size: 44 kDa

Observed band size: 53 kDa

Exposure time: 1 minute


Blocking & dilution buffer: 5% NFDM/TBST



Immunoprecipitation - Anti-p53 (phospho S20) antibody [EPR2156(2)] (ab157454)

Detection of p53 Western Blot of Immunoprecipitate. T47D cells treated with etoposide lysate immunoprecipitated using ab157454 at 1/10 dilution followed by HRP-conjugated anti-rabbit IgG, which preferentially detects the non-reduced form of rabbit IgG.

Anti-p53 (phospho S20) antibody [EPR2156(2)] (ab157454) at 1/1000 dilution + Immunoprecipitation pellet from T47-D cells treated with etoposide lysate at 10 µg



Western blot - Anti-p53 (phospho S20) antibody [EPR2156(2)] (ab157454)

All lanes : Anti-p53 (phospho S20) antibody [EPR2156(2)] (ab157454) at 1/1000 dilution

Lane 1 : T-47D cell lysate

Lane 2 : T-47D cell lysate treated with etoposide.


Lysates/proteins at 10 µg per lane.

Secondary

All lanes : Goat anti-rabbit HRP at 1/2000 dilution

Predicted band size: 44 kDa

Lower panel shows labeling with an anti-p53 C terminal antibody.



Primary antibody dilution: 1/1000

Secondary antibody: goat anti-rabbit IgG, (H+L), peroxidase conjugated

Secondary antibody dilution: 1/2500

Blocking & dilution buffer: 5% NFDm/TBST

Lane 1 sample: p53 (pS20) phospho peptide

Lane 2 sample: p53 non-phospho peptide

Exposure time: 10 seconds

Why choose a recombinant antibody?

<p>Research with confidence Consistent and reproducible results</p>	<p>Long-term and scalable supply Recombinant technology</p>
<p>Success from the first experiment Confirmed specificity</p>	<p>Ethical standards compliant Animal-free production</p>

Anti-p53 (phospho S20) antibody [EPR2156(2)]
(ab157454)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors